Efficacy of Baricitinib in Patients with Atopic Dermatitis and Atopic Comorbidities: Results of Pooled Data from 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-week Trials (BREEZE-AD1 and BREEZE-AD2)

被引：0
|
作者：
Wollenberg, Andreas [1 ]
Boguniewicz, Mark [2 ]
Travers, Jeffrey [3 ]
Thyssen, Jacob [4 ]
Goldblum, Orin [5 ]
Ball, Susan [5 ]
Sun, Luna [5 ]
Chen, Sherry [6 ]
Silverberg, Jonathan [7 ]
机构：
[1] Ludwig Maximillian Univ, Munich, Germany
[2] Natl Jewish Hlth, Denver, CO USA
[3] Wright State Univ, Dayton, OH 45435 USA
[4] Univ Copenhagen, Copenhagen, Denmark
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Syneos Hlth, Raleigh, NC USA
[7] Northwestern Univ, Feinberg Sch, Evanston, IL 60208 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
610
引用
收藏
页码：AB190 / AB190
页数：1
相关论文
共 50 条
  • [31] Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial
    Wollenberg, A.
    Nakahara, T.
    Maari, C.
    Peris, K.
    Lio, P.
    Augustin, M.
    Silverberg, J. I.
    Rueda, M. J.
    DeLozier, A. M.
    Pierce, E.
    Yang, F. E.
    Sun, L.
    Ball, S.
    Tauber, M.
    Paul, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (07) : 1543 - 1552
  • [32] Efficacy of dupilumab treatment in atopic hand and foot dermatitis across morphological subtypes: results from a phase 3, randomized, double-blind, placebo-controlled trial
    Worm, Margitta
    Simpson, Eric L.
    Honari, Golara
    Soong, Weily
    Pinter, Andreas
    Masuda, Koji
    Shao, Liyang
    Dubost-Brama, Ariane
    Bansal, Ashish
    Korotzer, Andrew
    Rossi, Ana B.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II60 - II60
  • [33] Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)
    Thaci, Diamant
    Simpson, Eric L.
    Deleuran, Mette
    Kataoka, Yoko
    Chen, Zhen
    Gadkari, Abhijit
    Eckert, Laurent
    Akinlade, Bolanle
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2019, 94 (02) : 266 - 275
  • [34] Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
    Mesinkovska, Natasha Atanaskova
    Ito, Taisuke
    Senna, Maryanne
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB50 - AB50
  • [35] Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study
    Fiorillo, Loretta
    Becker, Emily
    de Lucas, Raul
    Belloni-Fortina, Anna
    Maes, Peter
    Oberoi, Rajneet K.
    Paris, Maria
    Zhang, Wendy
    Zhang, Zuoshun
    Arkin, Lisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB122 - AB122
  • [36] Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
    Simpson, Eric L.
    Merola, Joseph F.
    Silverberg, Jonathan, I
    Reich, Kristian
    Warren, Richard B.
    Staumont-Salle, Delphine
    Girolomoni, Giampiero
    Papp, Kim
    de Bruin-Weller, Marjolein
    Thyssen, Jacob P.
    Zachariae, Rebecca
    Olsen, Christiana K.
    Wollenberg, Andreas
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (06) : 888 - 899
  • [37] Efficacy and Safety of GR1802 in Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Wang, Shangshang
    Zhang, Litao
    Liang, Yunsheng
    Zhang, Shifa
    Wang, Jingyan
    Man, Xiaoyong
    Ji, Chao
    Chen, Rixin
    Xiang, Guang
    Meng, Zudong
    Yang, Chunjun
    Cheng, Hao
    Wang, Qi
    Li, Lin-feng
    Zhang, Siping
    Ding, Yanfeng
    Zhu, Quangang
    Qin, Lanying
    Li, Yumei
    Lu, Qianjin
    Xia, Li
    Cao, Shuanglin
    Yu, Chunshui
    Duan, Xinsuo
    Wu, Liming
    Zhang, Chunlei
    Jiang, Congjun
    Wang, Wei
    Xu, Jinhua
    DERMATOLOGIC THERAPY, 2025, 2025 (01)
  • [38] Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies
    Papp, Kim
    Szepietowski, Jacek C.
    Kircik, Leon
    Toth, Darryl
    Eichenfield, Lawrence F.
    Leung, Donald Y. M.
    Forman, Seth B.
    Venturanza, May E.
    Sun, Kang
    Kuligowski, Michael E.
    Simpson, Eric L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (04) : 863 - 872
  • [39] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Reich, Kristian
    Teixeira, Henrique D.
    de Bruin-Weller, Marjolein
    Bieber, Thomas
    Soong, Weily
    Kabashima, Kenji
    Werfel, Thomas
    Zeng, Jiewei
    Huang, Xiaohong
    Hu, Xiaofei
    Hendrickson, Barbara A.
    Ladizinski, Barry
    Chu, Alvina D.
    Silverberg, Jonathan I.
    LANCET, 2021, 397 (10290): : 2169 - 2181
  • [40] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: results from the pivotal phase III, randomized, double-blind, placebo-controlled AD Up study
    Reich, K.
    Teixeira, H. D.
    De Bruin-Weller, M.
    Bieber, T.
    Soong, W.
    Kabashima, K.
    Werfel, T.
    Zeng, J.
    Huang, X.
    Hu, X.
    Ladizinski, B.
    Chu, A. D.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E59 - E60
12345